Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid for prevention of atrial fibrillation after CABG
IRCT20251023067736N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Bempedoic acid with Placebo (2 arms). Primary endpoints: Postoperative atrial fibrillation, C-reactive protein and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
bempedoic acid
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20251023067736N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251023067736N1.